Microglia Do Not Restrict SARS-CoV-2 Replication following Infection of the Central Nervous System of K18-Human ACE2 Transgenic Mice

Gema M. Olivarria, Yuting Cheng, Susana Furman, Collin Pachow, Lindsay A. Hohsfield, Charlene Smith-Geater, Ricardo Miramontes, Jie Wu, Mara S. Burns, Kate I. Tzourmas, Jennifer Stocksdale, Cynthia Manlapaz, William H. Yong, John Teijaro, Robert Edwards, Kim N. Green, Leslie M. Thompson, Thomas E. Lane

Gema M. Olivarria, Yuting Cheng, and Susana Furman contributed equally to this work. Author order was determined by performance of work, writing of the manuscript, experimental design, and intellectual contributions.

ABSTRACT Unlike SARS-CoV-1 and MERS-CoV, infection with SARS-CoV-2, the viral pathogen responsible for COVID-19, is often associated with neurologic symptoms that range from mild to severe, yet increasing evidence argues the virus does not exhibit extensive neuroinvasive properties. We demonstrate SARS-CoV-2 can infect and replicate in human iPSC-derived neurons and that infection shows limited antiviral and inflammatory responses but increased activation of EIF2 signaling following infection as determined by RNA sequencing. Intranasal infection of K18 human ACE2 transgenic mice (K18-hACE2) with SARS-CoV-2 resulted in lung pathology associated with viral replication and immune cell infiltration. In addition, ~50% of infected mice exhibited CNS infection characterized by wide-spread viral replication in neurons accompanied by increased expression of chemokine (Cxcl9, Cxcl10, Ccl2, Ccl5 and Ccl19) and cytokine (Ifn-χ and Tnf-α) transcripts associated with microgliosis and a neuroinflammatory response consisting primarily of monocytes/macrophages. Microglia depletion via administration of colony-stimulating factor 1 receptor inhibitor, PLX5622, in SARS-CoV-2 infected mice did not affect survival or viral replication but did result in dampened expression of proinflammatory cytokine/chemokine transcripts and a reduction in monocyte/macrophage infiltration. These results argue that microglia are dispensable in terms of controlling SARS-CoV-2 replication in the K18-hACE2 model but do contribute to an inflammatory response through expression of pro-inflammatory genes. Collectively, these findings contribute to previous work demonstrating the ability of SARS-CoV-2 to infect neurons as well as emphasizing the potential use of the K18-hACE2 model to study immunological and neuropathological aspects related to SARS-CoV-2-induced neurologic disease.

IMPORTANCE Understanding the immunological mechanisms contributing to both host defense and disease following viral infection of the CNS is of critical importance given the increasing number of viruses that are capable of infecting and replicating within the nervous system. With this in mind, the present study was undertaken to evaluate the role of microglia in aiding in host defense following experimental infection of the central nervous system (CNS) of K18-hACE2 with SARS-CoV-2, the
causative agent of COVID-19. Neurologic symptoms that range in severity are common in COVID-19 patients and understanding immune responses that contribute to restricting neurologic disease can provide important insight into better understanding consequences associated with SARS-CoV-2 infection of the CNS.

**KEYWORDS** SARS-CoV-2, microglia, central nervous system, neuropathology

The clinical spectrum of COVID-19 is complex, and numerous risk factors and comorbidities are considered important in affecting disease severity, including age, obesity, chronic respiratory disease, and cardiovascular disease (1). In addition, neurological symptoms are common in COVID-19 patients, suggesting the virus can potentially infect and replicate in the central nervous system (CNS). Indeed, encephalitis and meningitis have been reported in COVID-19 patients, and viral RNA and protein have been detected within the CSF of infected patients (2–4). Additionally, human brain organoids are susceptible to SARS-CoV-2 infection (2, 5), yet demonstration of extensive CNS penetrance by SARS-CoV-2 has remained elusive. It is imperative to develop pre-clinical animal models of COVID-19 that capture consistent and reproducible clinical and histologic readouts of many disease-associated symptoms following experimental infection with clinical isolates of SARS-CoV-2 (6). Importantly, these models should be able to reliably evaluate interventional therapies to limit viral replication and mute immune-mediated pathology, as well as evaluate effectiveness of novel vaccines, all while remaining cost-effective. To date, the most common animal models employed to evaluate COVID-19 pathogenesis include mice, nonhuman primates (rhesus macaques, cynomolgus macaques and African green monkeys), Syrian hamsters, ferrets, and cats (6).

Human ACE2 (hACE2) transgenic mouse models have provided important insights into the pathogenesis of COVID-19. Perlman and colleagues (7) developed the K18-hACE2 mice, initially used as a mouse model of SARS-CoV-1, which has been successfully employed as a model of COVID-19 (8). Intranasal inoculation of SARS-CoV-2 in K18-hACE2 mice results in a dose-dependent increase in weight loss and mortality with the lung being the major site of viral infection, while smaller amounts of virus are detected in the heart, liver, spleen, kidney, small intestine, and colon (8). Examination of lungs revealed distribution of viral antigen associated with alveolar damage, interstitial lesions, edema, and inflammation. Lung infection resulted in an increase in expression of interferons as well as inflammatory cytokines and chemokines associated with neutrophil, macrophage/monocyte, and T cell infiltration. Viral RNA was also detected within the sinonasal epithelium, and viral antigen was present in sustentacular cells associated with anosmia (8).

Examination of brains of SARS-CoV-2 infected hACE2 transgenic mice has indicated that infection of the CNS is not consistent, and in some cases, virus is rarely detected (8–12). This may reflect the SARS-CoV-2 isolate being studied as well as the dose of virus being administered. However, in those animals in which virus penetrates the brain, there can be extensive spread of the virus throughout different anatomic regions accompanied by cell death (8), and these results are consistent with early studies examining SARS-CoV-1 infection of K18-hACE2 mice (7). High-level of CNS infection in K18-hACE2 is accompanied by meningeal inflammation associated with immune cell infiltration into the brain parenchyma and microglia activation (11). Enhanced CNS penetrance and replication of SARS-CoV-2 within the CNS of K18-hACE2 is associated with increased mortality, although the mechanisms by which this occurs remain unclear. The present study was undertaken to (i) expand on earlier studies examining SARS-CoV-2 infection of human CNS resident cells, (ii) evaluate the immune response that occurs in response to SARS-CoV-2 infection of the CNS of K18-hACE2 mice, and (iii) assess the contributions of microglia in host defense following CNS infection by SARS-CoV-2.

**RESULTS**

**SARS-CoV-2 infection of human neurons.** Previous studies have indicated neurons are susceptible to infection by SARS-CoV-2 (2); therefore, we infected human
iPSC-derived neurons with SARS-CoV-2. Similar to earlier reports, SARS-CoV-2 was able to infect and replicate within neurons as determined by staining for nucleocapsid protein (Fig. 1A and B). By 48h pi., viral nucleocapsid protein had spread from the neuron cell body and extended down dendritic and axonal projections (Fig. 1C and D). Notably, we did not detect syncytium formation in neuron cultures at any time following infection with SARS-CoV-2, suggesting that virus may not spread via fusion with neighboring cells. RNA sequencing analysis revealed that expression of both antiviral and inflammatory responses in infected neurons was limited relative to the genes within the heatmap at both 24h and 48h postinfection (Fig. 1E). We then evaluated pathways that may progressively change between 24h and 48h postinfection comparing the Transcripts per million (TPMs) as input for Ingenuity Pathway Analysis (IPA). Figure 1F shows the top 12 IPA canonical pathways that are overrepresented. eIF2 signaling is the predominant pathway induced upon SARS-CoV-2 infection of neurons, followed by pathways associated with oxidative phosphorylation, eIF4, MTOR signaling and mitochondrial dysfunction, the latter with no prediction of activity. Notably, the Coronavirus Pathogenesis Pathway is also overrepresented; however, is inhibited in response to neuronal infection by SARS-CoV-2 over the time frame tested with the majority of the genes represented encoding ribosomal proteins (Fig. 1F).

SARS-CoV-2 infection of lungs of K18-hACE2 mice. K18-hACE2 mice were intranasally infected with either 1 × 10^4, 5 × 10^4 or 1 × 10^5 PFU of SARS-CoV-2, and weight loss and mortality were recorded. Consistent with other reports (8–12), we observed a general trend toward dose-dependent increase in weight loss and mortality out to day 7 postinfection (pi.) (Fig. 2A). qPCR indicated the presence of viral RNA in lungs of infected K18-hACE2 (Fig. 2B). In situ hybridization of lungs of mice infected with 5 × 10^4 PFU of virus at day 7 pi. revealed localized areas of viral infection as determined by expression of spike RNA (Fig. 2C). Hematoxylin and eosin staining of lungs demonstrated both alveolar and interstitial lesions, with alveolar hemorrhage and edema (Fig. 2D), interstitial congestion (Fig. 2E) and lymphocytic infiltrates (Fig. 2F). qPCR analysis of proinflammatory cytokines and chemokines indicated increased expression of Ifn-λ, Cxcl10, Cxcr2, and Ccl2 yet varied expression of Il-10, TNF-α, Ccl19, and Ccl5 and limited expression of transcripts for Ifn-β1 (Fig. 2G). Hematoxylin and eosin staining showed immune cell infiltrates in SARS-CoV-2-infected lungs containing inflammatory CD8+ T cells as determined by immunofluorescent staining (Fig. 3A to D). In addition, germinal center-like structures were detected within the lungs of SARS-CoV-2-infected mice with enriched CD8+ T cell accumulation (Fig. 3E and F). Collectively, our findings are consistent with previous studies employing SARS-CoV-2 infection of K18-hACE2 mice in terms of development of interstitial pneumonia and immune cell infiltration associated with viral RNA present within the lungs (8–12).

Neuroinvasion by SARS-CoV-2. Following intranasal infection of mice with 5 × 10^4 PFU of SARS-CoV-2, virus was detected in the brain as determined by qPCR and RNAscope compared to sham-infected mice (Fig. 4A to C). Using a Spike-specific probe, we observed wide-spread expansion of viral mRNA throughout the brain with many distinct anatomical regions infected as well as spared. By day 7 pi., viral RNA was present within the cortex (CTX), striatum (STR), pallidum (PAL), thalamus (TH), hypothalamus (HY), midbrain (MB), pons (P), and medulla (MD), whereas areas that were relatively spared included the olfactory bulb (OB), white matter (WM) tracts, hippocampus (HC) and cerebellum (CB) (Fig. 4B); no viral RNA was detected in sham-infected K18-hACE2 mice (Fig. 4C). Demyelinating lesions have been detected in postmortem brains of COVID-19 patients (13); however, we did not detect any evidence of demyelination within the brains of SARS-CoV-2-infected mice as determined by luxol-fast blue (LFB) staining (Fig. 4D and E). The predominant cellular target for SARS-CoV-2 infection was neurons as determined by cellular morphology of cells positive for viral RNA (Fig. 5A and B). In a small percentage of infected mice, we were able to detect viral RNA in the olfactory bulb with primary targets being mitral and glomerular neurons (Fig. 5C and D). Prominent neuropathological changes detected included perivascular cuffing (Fig.
FIG 1 SARS-CoV-2 infects human iPSC-derived neurons. (A) hiPSC-derived neurons were infected with SARS-CoV-2 at an MOI of 0.1, immunostained with anti-MAP2 and anti-SARS-CoV-2 N, and imaged at 0, 24, and 48 h postinfection. (B) Quantification of SARS-CoV-2 GFP (Continued on next page)
SE), subventricular inflammation (Fig. 5F) and leptomeningitis (Fig. 5G), consistent with previous studies (2, 3).

Analysis of CNS myeloid cells showed increased IBA1 soma size and shortened/thickened processes, indicative of microglial activation in SARS-CoV-2-infected mice compared to sham-infected mice (Fig. 6A and B). In addition, immunofluorescent co-staining for Mac2/galectin-3+ cells, a marker recently identified in peripheral cell infiltrates, and IBA1 (Hohsfeld et al. manuscript in revision), revealed increased monocyte/macrophage infiltration within the brains of infected mice compared to sham-infected mice (Fig. 6A and B). Mac2+ cells enter the CNS parenchyma from different anatomic areas, including the ventricles, leptomeninges and vasculature (Fig. 6C and D) compared to uninfected control mice (Fig. 6E).

Microglia ablation does not affect disease or control of viral replication in the CNS. Previous studies have implicated the importance of microglia in aiding in control of neuroadapted murine beta-coronaviruses by enhancing antiviral T cell responses through augmenting antigen presentation (11–13). Notably, microglia are dependent on signaling through the colony-stimulating factor 1 receptor (CSF1R) for their survival and can be effectively eliminated with CSF1R inhibitors that cross the blood brain barrier (14). K18-hACE2 mice were fed pre-formulated chow containing either the CSF1R inhibitor PLX5622 (1,200 ppm) (15) or control chow 7 days prior to intranasal infection with 5 × 10^4 PFU of SARS-CoV-2, and remained on drug for the duration of the experiment (6). No notable differences were detected in weight loss between experimental groups (Fig. 7A). SARS-CoV-2-infected mice treated with either PLX5622 or control chow were sacrificed at day 7 pi., and viral mRNA levels in lungs and brains were determined. As shown in Fig. 7B, we detected no significant differences in the Spike mRNA transcripts in either the lung or the brain between experimental groups. Quantification of Iba1-positive cells revealed a >95% reduction (P < 0.01) in microglia in PLX5622-treated mice compared to control mice. Overall, PLX5622-mediated ablation of microglia resulted in a dramatic reduction in expression of proinflammatory cytokine/chemokine genes within the brains of SARS-CoV-2 infected mice compared to infected mice fed control chow (Fig. 7D). By day 7 pi., SARS-CoV-2 infection resulted in increased expression of proinflammatory cytokines and chemokines in mice treated with control chow. The highest transcript levels were for the T cell chemoattractants CXCL9 and CXCL10; monocyte/macrophage chemoattractants, CCL2 and CCL5; and TNF-α (Fig. 7D). Transcripts encoding the neutrophil chemoattractant CXCL1, and B cell chemoattractant CCL19 were also increased, as well as IFN-α type 3 and IL-10 compared to uninfected controls (Fig. 7D). Depletion of microglia resulted in a marked reduced expression of the majority chemokine/ cytokines transcripts. While not significant, there was a marked reduction in Mac2/galectin3+ cells in PLX5622-treated mice compared to control chow and this correlated with reduced expression of monocyte/macrophage chemoattractant chemokines CCL2 and CCL5 (Fig. 7E) that have previously been shown to attract these cells into the CNS of mice infected with a neurotropic mouse coronavirus (16–21).

**DISCUSSION**

In the face of the ongoing COVID-19 pandemic, it is imperative to develop pre-clinical animal models of COVID-19 that capture consistent and reproducible clinical and histologic readouts of many disease-associated symptoms following experimental infection with SARS-CoV-2 [1]. For both SARS-CoV-2 and SARS-CoV-1, the surface-bound viral spike glycoprotein uses the cellular surface receptor protein, ACE2, to bind and enter cells. However, mouse ACE2 does not efficiently bind the spike glycoprotein...
of either SARS-CoV-1 or SARS-CoV-2, rendering wild-type mice not useful in the study of SARS or COVID-19 pathogenesis, respectively, due to an inefficient ability to infect and replicate in host cells. Human ACE2 (hACE2) transgenic mouse models have provided important insights into the pathogenesis of COVID-19 in terms of evaluating the efficacy and duration of immune responses elicited in response to infection as well as

![Graph showing percent weight change of K18-hACE2 and WT mice infected with indicated dose of SARS-CoV-2. CS7BL/6 wild-type (WT) mice (n = 3) were infected with 1 × 10^6 PFU. K18-hACE2 mice were infected intranasally with SARS-CoV-2 at either 1 × 10^6 PFU (n = 17), 5 × 10^6 PFU (n = 4), or 1×10^7PFU (n = 8).](image)

**FIG 2** SARS-CoV-2 infection of lungs of K18-hACE2 mice. (A) Percent weight change of K18-hACE2 and WT mice infected with indicated dose of SARS-CoV-2. CS7BL/6 wild-type (WT) mice (n = 3) were infected with 1 × 10^6 PFU. K18-hACE2 mice were infected intranasally with SARS-CoV-2 at either 1 × 10^6 PFU (n = 17), 5 × 10^6 PFU (n = 4), or 1×10^7PFU (n = 8). (B) Quantitative PCR with primers for Spike mRNA on uninfected and SARS-CoV-2-infected mouse lung tissue. dCt values are derived from the difference between the Ct values of Spike mRNA and a housekeeping gene, GAPDH. Lower dCt values indicate increased viral mRNA. (C) K18-hACE2 mouse lung tissue at day 7 pi. with 5 × 10^6 PFU SARS-CoV-2 showing localized Spike mRNA expression as determined by RNAscope. Representative H&E images from lungs of SARS-CoV-2-infected mice (5 × 10^6 PFU) showing (D) airway edema, vascular congestion and intra-alveolar hemorrhage, (E) peribronchiolar lymphocytic cuffing, and (F) interstitial vascular congestion and lymphocytic infiltrates. (G) Quantitative PCR shows the fold changes of the indicated genes in two infected mouse lungs compared to uninfected mice. Data presented in A are representative of two independent experiments.
testing vaccines, antiviral drugs and monoclonal antibody therapies to restrict viral replication and limit disease severity (8).

Intranasal inoculation of K18-hACE2 mice with SARS-CoV-2 resulted in weight loss along with viral infection and replication within the lungs that was associated with a robust inflammatory response. These findings are consistent with other reports that demonstrated the presence of neutrophils, monocytes/macrophages and T cells within the lungs of SARS-CoV-2-infected K18-hACE2 mice (8, 11). In response to infection, expression of proinflammatory cytokines/chemokines was increased and correlated with the presence of inflammatory cells. We detected inflammatory CD8⁺ T cells in the lungs of infected mice and these cells are presumably responding to the T cell chemoattractant CXCL10. Our lab has previously shown that induction of CXCL10 expression following experimental infection of mice with a neuroadapted strain of murine coronavirus is critical in host defense and acts by attracting virus-specific T cells into the CNS (22–24). Similarly, inflammatory monocyte/macrophages are likely recruited in response to expression of CCL2 as this has been shown to attract these cells following murine coronavirus infection of mice (16–19). The increased expression of transcripts encoding CXCR2 most likely reflects the presence of inflammatory neutrophils (25). Therapeutic targeting of these chemokines may therefore alter immune cell trafficking into the lungs of infected mice and alleviate the severity of lung pathology. How blocking chemokine signaling would affect SARS-CoV-2-induced lung pathology in COVID-19 patients is under investigation.

Clinical reports of COVID-19 patients cite a dysregulated immune response characterized by elevated chemokine expression as key in the development of pathogenesis (26, 27). Similar to our findings using the K18-hACE2 model, these reports have found...
upregulation of CCL2 (MCP1), CXCL8 (IL-8), and CXCL10 (IP10) to correlate with severity of disease and have suggested evaluation of these as biomarkers for disease and as targets for therapeutic intervention (28–30). Leronlimab, a CCR5-blocking antibody, is currently in phase 2 clinical trials in the United States for treatment of mild, moderate, and severe COVID-19 (NCT04343651, NCT04347239). In addition, limiting neutrophil infiltration into the lungs of COVID-19 patients may help prevent disease progression and outcome. With this in mind, the monoclonal antibody BMS-986253 that blocks CXCL8 as well as Reparixin, an oral inhibitor of CXCR1/2, are both currently undergoing clinical trials in the United States for reducing the severity of COVID-19-related pneumonia by reducing neutrophil accumulation within the lungs of infected patients (NCT04878055, NCT04347226). A clinical trial was recently completed using measurement of CXCL10 in a Clinical Decision Support Protocol in COVID-19 patients (NCT04389645) that positively correlated CXCL10 levels with mortality suggesting that targeting CXCL10 signaling may also be beneficial in managing disease severity (31).

Examination of brains of SARS-CoV-2-infected K18-human-ACE2 mice, as well as brains from other hACE2 transgenic mice, has revealed that virus is able to infect, replicate and spread within the parenchyma and this is considered important in contributing to mortality (2, 5, 8, 9). Virus can be detected in different anatomic regions of the brain and is accompanied by cell death (5) and these observations are consistent with early studies examining SARS-CoV-1 infection of K18-human-ACE2 mice (7). Our results indicate that neurons are primary targets for SARS-CoV-2 infection within the brains of K18-human-ACE2 mice which is consistent with other studies (10, 32, 33). Furthermore, human iPSC-derived neurons were susceptible to SARS-CoV-2 infection and virus was able to replicate in these cells. The detection of viral antigen within dendrites extending from the cell body suggests this may offer a unique mechanism of viral replication and spread in neurons and this is further emphasized by the absence of cell death and/or syncytium formation. RNA sequencing of infected neurons revealed that expression of most inflammatory and antiviral response genes were reduced in SARS-CoV-2-infected neurons, consistent with a previously published study highlighting the muted immune response in neurons infected with SARS-CoV-2 compared to Zika virus (2). However, IPA analysis determined that despite the lack of induced immune and inflammatory response in infected neurons, there was a significant overrepresentation of pathways

---

**FIG 4** Widespread neuroinvasion by SARS-CoV-2 of K18 human-ACE2 mice. (A) Quantitative PCR with primers for Spike mRNA on uninfected (n = 5) and SARS-CoV-2-infected mouse brain tissue (n = 4) at day 7 pi. dCt values are derived from the difference between the Ct values of Spike mRNA and the housekeeping gene, GAPDH. *In situ* hybridization for Spike viral mRNA in (B) SARS-CoV-2-infected and (C) sham-infected K18-hACE2 mice. Anatomical regions in which viral RNA is detected (indicated in red) are indicated: cortex (CTX), striatum (STR), pallidum (PAL), thalamus (TH), hypothalamus (HY), midbrain (MB), Pons (P), and medulla (MD), whereas areas that were relatively spared included the olfactory bulb (OB), white matter (WM) tracts and hippocampus (HC) (D) Representative brain from SARS-CoV-2 infected brain from panel B stained with LFB demonstrates lack of demyelination with (E) high-power image of myelin tract showing no inflammation or demyelination. Data presented in A are representative of two independent experiments.
associated with eIF2, oxidative phosphorylation, regulation of eIF4 and mTOR signaling. eIF2, which mediates initiation of eukaryotic translation by binding Met-tRNA^{Met} to the ribosomal subunit, can be activated via phosphorylation by various kinases, including protein kinase-RNA-dependent (PKR), PKR-like endoplasmic reticulum kinase (PERK), and heme regulated inhibitor (HRI) (34). Upregulation of eIF2 phosphorylation by these can occur in response to various types of stressors, including viral infection, ER stress, or oxidative stress, respectively (34). Upregulation of eIF4, which mediates recruitment of ribosomes to mRNA for translation, alongside overactivation of mTOR signaling, which modulates eIF4 activity, suggests infection of neurons with SARS-CoV-2 induces increased cellular activity and protein production even in the absence of inflammatory and antiviral gene induction (35). Whether this increase in protein production pathways corresponds to viral hijacking of cellular machinery for viral reproduction or if it corresponds to other induced mechanisms of neuronal stress/survival response remains to be determined.

Resident cells of the CNS are important in host defense following viral infection through either secretion of antiviral cytokines like type I interferon (IFN-I) and pro-inflammatory cytokines/chemokines, and presentation of antigen to infiltration of antigen-sensitized T cells. We found the transcripts encoding the T cell chemoattractant chemokines, including CXCL9 and CXCL10 were expressed along with monocyte/
macrophage chemokines CCL2 and CCL5 and CXCL1 which attracts neutrophils. In addition, transcripts specific for the B cell chemoattractant CCL19 were also detected. The chemokine elicited in response to CNS infection of K18-hACE2 by SARS-CoV-2 infection is remarkably similar to the chemokine response following CNS infection of mice with the neuroadapted strains of murine coronaviruses (36, 37). This is interesting in that murine coronavirus are primarily tropic for glial cells, e.g., astrocytes, microglia and oligodendrocytes with relative sparing of neurons while neurons appear to be exclusively targeted by SARS-CoV-2. These findings argue that expression of chemokines following coronavirus infection of the CNS may not be influenced by the cellular target of infection and this may reflect a localized response to expression of interferons (IFN) expressed in response to viral infection. With this in mind, we did detect IFNα3 transcripts within the brains of SARS-CoV-2 infected mice yet IFNβ1 transcripts were noticeably reduced. The inflammatory response consisted primarily of monocytes/macrophages as determined by immunofluorescent staining for Mac2 and these cells are most likely migrating into the CNS in response to CCL2 and CCL5 expression (18–21). We did not detect a robust T cell response and this was surprising given the expression levels of CXCL9 and CXCL10 transcripts. Whether this simply reflected that T cells had yet to migrate into the brains of infected mice at the time of sacrifice or if efficient translation of these transcripts is compromised is not known at this time.

We have recently determined that in response to JHMV infection of the CNS of immunocompetent mice, there are inflammatory monocyte/macrophage subpopulations that differentially express CD115/CSF-1R and this highlights the highly inflammatory nature of these cells in models of neurodegeneration (37). Expression of CD115-expressing macrophages and microglia have also been detected in other models of neuroinflammation demonstrating important roles for these cells in contributing to inflammatory responses (38–40). More recently, microglia are recognized to be important in host defense in response to viral infection of the CNS (41–45). Targeted

**FIG 6** SARS-CoV-2 infection of K18 human-ACE2 mice results in microgliosis and myeloid cell infiltration. Brains from either SARS-CoV-2 or sham-infected mice were removed at day 7 pi. to evaluate immune cell infiltration. Microglia activation and monocyte infiltration were determined in sham-infected mice (A) and SARS-CoV2 infected mice (B) by staining for expression of Iba1 (red) and Mac2/galectin 3 (green), respectively. Infiltration of peripheral monocytes into the SARS-CoV-2 infected brain parenchyma occurs via the vasculature (C) as well as ventricular and leptomeningeal spaces (D) compared to uninfected control mice (E).
FIG 7 Microglia ablation does not impact control of viral replication in the CNS. (A) Weight loss of K18-hACE2 mice infected intranasally with $5 \times 10^4$ PFU of SARS-CoV-2 that were fed either control chow ($n = 4$) or PLX5622-formulated chow ($n = 4$). (B) Quantitative PCR in the brains (Continued on next page)
depletion of microglia via CSF1R inhibition leads to increased mortality in mice infected with West Nile Virus (WNV) and is associated with diminished activation of antigen-presenting cells (APCs) and limited reactivation of virus-specific T cells that leads to reduced viral clearance (42, 44). Similar findings have been reported for other neurotropic viruses, including Japanese encephalitis virus (JEV) (44) and Theiler’s murine encephalomyelitis virus (TMEV) (43, 45). Moreover, microglia have also been shown to enhance host defense following CNS infection by the neurotropic JHM strain of mouse hepatitis virus (JHMV, a murine coronavirus) and this was related to inefficient T cell-mediated control of viral replication (41, 46). Additionally, the absence of microglia also results in an increase in the severity of demyelination, accompanied by a decrease in remyelination (46, 47). In response to SARS-CoV-2 CNS infection, we did detect microgliosis indicating these cells are responding to infection and may be involved in host defense. Ablation of microglia via PLX5622 administration did not affect clinical disease nor viral burden within the brain indicating these cells are dispensable in terms of controlling SARS-CoV-2 replication within the brain in the K18-hACE2 model. There was a marked reduction in expression of proinflammatory cytokines/chemokines, including monocyte/macrophage chemoattractants CCL2 and CCL5 and this corresponded with an overall reduction in numbers of these cells in the brains of PLX5622-treated mice. These findings support the notion that microglia do contribute to the neuroinflammatory response, in part, through influencing expression of chemokines/chemokines in response to SARS-CoV-2 infection of the CNS of K18-hACE2 mice.

Very early in the COVID-19 pandemic, it became apparent that an abundant number of patients exhibited a variety of neurologic conditions that ranged in severity. Although numerous neurological symptoms have been associated with COVID-19, the most common neurologic symptoms include anosmia/dysgeusia, delirium, encephalopathy, and stroke (48–50). The overwhelming evidence indicates that SARS-CoV-2 is not readily detected within the CNS by either PCR and/or immunohistochemical staining (2, 51) suggesting that neurologic complications associated with COVID-19 patients may occur through alternative mechanisms, including the potential development of autoreactive antibodies specific for neural antigens (52). COVID-19 patients have anti-SARS-CoV-2 IgG antibodies in the cerebral spinal fluid (CSF) that recognized target epitopes that differ from serum antibodies. Moreover, a portion of COVID-19 patients exhibited CSF antibodies that targeted self-antigens, arguing for the possibility that neurologic disease may be associated with CNS autoimmunity (52). Nonetheless, neurons and cells of the vasculature have been shown to be targets of infection (53–57). Despite increasing evidence indicating extensive SARS-CoV-2 infection of the CNS does not occur, autopsy findings indicate the presence of microglia nodules, astrocyte activation and CD8+ T cell infiltration in the brain, providing evidence for immune responses occurring within the CNS of infected patients (3, 58, 59). Related to this, a recent study indicated microglia nodules interacting with inflammatory CD8+ T cells within distinct anatomical regions of the brains of COVID-19 patients and this correlated with altered systemic inflammation (60). It is incontrovertible that transgenic hACE2 models, particularly the K18-hACE2 model, have provided a better understanding of the pathogenesis of COVID-19 yet the one notable and consistent drawback of many of these models is the ability of virus to infect, efficiently replicate, and spread within the parenchyma, which contributes to increased mortality. These findings emphasize the importance of working with animal models in which SARS-CoV-2 entry

FIG 7 Legend (Continued)
into the CNS is more consistent with what has been observed in COVID-19 patients.

MATERIALS AND METHODS

Mice and viral infection. All experiments were performed in accordance with animal protocols approved by the University of California, Irvine Institutional Animal Care and Use Committee.8–16 week-old heterozygous K18-HACE2 C57BL/6 (strain: B6.Cg-Tg(K18-ACE2)2Prfmm/J) mice were obtained from Jackson Laboratory. Animals were housed by sex in single use disposable plastic cages and provided ad-libitum water. SARS-CoV-2 isolate USA-WA1/2020 was obtained from BEI. Mice were inoculated with intranasal passages of SARS-CoV-2 in 10 μl of DMEM or sham inoculated. Inoculations were performed under light anesthesia through an intraperitoneal injection of a mixture of ketamine and xylazine. Infected and uninfected mice were examined and weighed daily. Animals were euthanized early if they reached predetermined euthanasia criteria.

iPSC-neuronal differentiation. iPSC line iCS331CTR3n1 was previously derived, characterized (61) and maintained as described at 37°C, 5% CO2 on hESC Matrigel (Fisher Scientific). Cells were thawed into LIA medium (ADF supplemented with 2 mM Glutamax, 2% B27 without vitamin A, 0.2 mM Y-27632 dihydrochloride for the first day post-thaw for further neural differentiation and subsequent daily feedings with LIA without Y-27632 dihydrochloride. Differentiated neurons were plated at 1 × 106 cells per well in 6-well plate format or at 8x105 cells per chamberslide well for imaging. Cells were infected with either pseudovirus or SARS-CoV-2 at d46-50 after start of differentiation.

SARS-CoV-2 infection of iPSC-derived neurons. SARS-CoV-2 isolate USA-WA1/2020 was obtained from BEI. Media was removed from cells and replaced with virus-containing media (or nonvirus media at 104 and 105 PFU of SARS-CoV-2 in 10 μl of DMEM or sham inoculated. Inoculations were performed under light anesthesia through an intraperitoneal injection of a mixture of ketamine and xylazine. Infected and uninfected mice were examined and weighed daily. Animals were euthanized early if they reached predetermined euthanasia criteria.

iPSC-neuronal differentiation. iPSC line iCS331CTR3n1 was previously derived, characterized (61) and maintained as described at 37°C, 5% CO2 on hESC Matrigel (Fisher Scientific catnumber 08774552) with daily feeding of mTeSR™ (Stem Cell Technologies catnumber 85850) (62). Neuronal differentiation was performed using the protocol described (62) with a modification that the cells were frozen at the neural progenitor stage at day 8 in CryoStor CS10 (Stem Cell Technologies number 07931). Cells were thawed into LJ medium (ADF supplemented with 2 mM Glutamax, 2% B27 without vitamin A, 0.2 μM LDN 193189 and 1.5 μM IWR1 20 ng/ml Activin A (Peprotech number 120-14E) containing 10 μM Y-27632 dihydrochloride for the first day post-thaw for further neural differentiation and subsequent daily feedings with LJ without Y-27632 dihydrochloride. Differentiated neurons were plated at 1 × 106 cells per well in 6-well plate format or at 8x105 cells per chamberslide well for imaging. Cells were infected with either pseudovirus or SARS-CoV-2 at d46-50 after start of differentiation.

SARS-CoV-2 infection of iPSC-derived neurons. SARS-CoV-2 isolate USA-WA1/2020 was obtained from BEI. Media was removed from cells and replaced with virus-containing media (or nonvirus media at 104 and 105 PFU of SARS-CoV-2 in 10 μl of DMEM or sham inoculated. Inoculations were performed under light anesthesia through an intraperitoneal injection of a mixture of ketamine and xylazine. Infected and uninfected mice were examined and weighed daily. Animals were euthanized early if they reached predetermined euthanasia criteria.

iPSC-neuronal differentiation. iPSC line iCS331CTR3n1 was previously derived, characterized (61) and maintained as described at 37°C, 5% CO2 on hESC Matrigel (Fisher Scientific catnumber 08774552) with daily feeding of mTeSR™ (Stem Cell Technologies catnumber 85850) (62). Neuronal differentiation was performed using the protocol described (62) with a modification that the cells were frozen at the neural progenitor stage at day 8 in CryoStor CS10 (Stem Cell Technologies number 07931). Cells were thawed into LJ medium (ADF supplemented with 2 mM Glutamax, 2% B27 without vitamin A, 0.2 μM LDN 193189 and 1.5 μM IWR1 20 ng/ml Activin A (Peprotech number 120-14E) containing 10 μM Y-27632 dihydrochloride for the first day post-thaw for further neural differentiation and subsequent daily feedings with LJ without Y-27632 dihydrochloride. Differentiated neurons were plated at 1 × 106 cells per well in 6-well plate format or at 8x105 cells per chamberslide well for imaging. Cells were infected with either pseudovirus or SARS-CoV-2 at d46-50 after start of differentiation.

SARS-CoV-2 infection of iPSC-derived neurons. SARS-CoV-2 isolate USA-WA1/2020 was obtained from BEI. Media was removed from cells and replaced with virus-containing media (or nonvirus media at 104 and 105 PFU of SARS-CoV-2 in 10 μl of DMEM or sham inoculated. Inoculations were performed under light anesthesia through an intraperitoneal injection of a mixture of ketamine and xylazine. Infected and uninfected mice were examined and weighed daily. Animals were euthanized early if they reached predetermined euthanasia criteria.

iPSC-neuronal differentiation. iPSC line iCS331CTR3n1 was previously derived, characterized (61) and maintained as described at 37°C, 5% CO2 on hESC Matrigel (Fisher Scientific catnumber 08774552) with daily feeding of mTeSR™ (Stem Cell Technologies catnumber 85850) (62). Neuronal differentiation was performed using the protocol described (62) with a modification that the cells were frozen at the neural progenitor stage at day 8 in CryoStor CS10 (Stem Cell Technologies number 07931). Cells were thawed into LJ medium (ADF supplemented with 2 mM Glutamax, 2% B27 without vitamin A, 0.2 μM LDN 193189 and 1.5 μM IWR1 20 ng/ml Activin A (Peprotech number 120-14E) containing 10 μM Y-27632 dihydrochloride for the first day post-thaw for further neural differentiation and subsequent daily feedings with LJ without Y-27632 dihydrochloride. Differentiated neurons were plated at 1 × 106 cells per well in 6-well plate format or at 8x105 cells per chamberslide well for imaging. Cells were infected with either pseudovirus or SARS-CoV-2 at d46-50 after start of differentiation.

SARS-CoV-2 infection of iPSC-derived neurons. SARS-CoV-2 isolate USA-WA1/2020 was obtained from BEI. Media was removed from cells and replaced with virus-containing media (or nonvirus media at 104 and 105 PFU of SARS-CoV-2 in 10 μl of DMEM or sham inoculated. Inoculations were performed under light anesthesia through an intraperitoneal injection of a mixture of ketamine and xylazine. Infected and uninfected mice were examined and weighed daily. Animals were euthanized early if they reached predetermined euthanasia criteria.
then 60°C for 1 min). Ct values for each sample were normalized to an internal control (GAPDH), yielding the ΔCt values. ΔCt values of infected or PLX-treated samples were compared to appropriate control samples, as indicated, to produce ΔΔCt values. The relative fold change between samples used in the ddCT calculation was calculated \(2^{-\Delta\Delta C_{\text{T}}}}. \)

**qPCR statistical analysis.** Statistical analysis was performed in Prism (GraphPad Software). The Brown-Forsythe and Welch’s ANOVA tests were used to compare the means between groups. Dunnnett’s test to correct for multiple comparisons was performed when necessary.

**mRNA-Seq.** Total RNA was isolated using the Qiagen RNeasy kit and QiAshredder for cell lysis. One microgram of RNA with RNA integrity number values ≥9 was used for library preparation using the strand-specific Illumina TruSeq mRNA protocol. Libraries were sequenced on the NovaSeq 6000 platform using 100 cycles to obtain paired-end 100 reads at >30 million reads per sample. For RNA-seq analysis, fastq files were trimmed using a base quality score threshold of >20 and aligned to the hg38 genome with Hisat 2. Reads passing quality control were used for quantification using featureCounts and analyzed with the DESeq2 R package to identify DEGs. Genes passing an FDR of 10% were used for GO enrichment analysis using GOrilla (27) (http://cbl-gorilla.cs.technion.ac.il/). For the heatmaps, a list of genes from GO:0006955 immune response and GO:0006954 inflammatory response was used. From those lists, the genes with the top 100 most variable TPM were plotted using the R package heatmap.

For the 48h versus 24h IPA, the TPM of all genes in the 1_Infected_24h sample were subtracted from the TPM of all genes in the 2_Infected_48h sample. The list of genes was sorted by the difference and the top 400 and bottom 400 selected to use as input for IPA’s core analysis.

**Histology and immunohistochemical staining.** Mice were euthanized at defined time points post-infection and tissues harvested according to IACUC-approved guidelines. Tissues were collected and placed in either cold TRIzol for qPCR analysis or 4% PFA for fixation and subsequent histological analysis. Following fixation, the 24–48h brains were either cryoprotected in 30% sucrose, embedded in O.C.T. (Fisher HealthCare), and sliced via Cryostat in 10 μm sagittal sections. Alternatively, tissues were dehydrated and paraffin-embedded and subsequently use for RNAscope or hematoxylin/eosin (H&E) in combination with luxol fast blue (LFB) to assess demyelination within the brains of experimental mice. For immunohistochemical staining of O.C.T.-embedded tissues, slides were rinsed with PBS to remove residual O.C.T., and antigen retrieval (incubation with 10 mM sodium Citrate at 95°C for 15 min) was performed if required for specific antigens at which point samples were incubated with 5% normal goat serum and 0.1% Triton-X, followed by overnight incubation at 4°C with primary antibodies. Several primary antibodies were used, including Iba1 (1:500 Wako), GFAP (1:1000 Abcam), Mac2/Galactin-3 (1:500, CL942AP Cedarlane), CD4 (1:200 Abcam), CD8 (1:200 Abcam), MHC I (1:200 Abcam), and MHC II (1:200 Abcam). On the second day, slides were treated with appropriate secondary antibodies (1:1000 goat anti-rat/rabbit Invitrogen, 1:1000 goat anti-chicken, Abcam) following PBS rinsing. Slides were then mounted with DAPI Fluoromount-G (SouthernBiotech). High-resolution fluorescent images were obtained using a Leica TCS SPE-II confocal microscope and LAS-X software. For whole brain stitches, automated slide scanning was performed using a Zeiss AxioScan.Z1 equipped with a Colibri camera and Zen Axioscan 2.3 software. Microglial morphology was determined using the filaments module in Bitplane Imaris 7.5, as described previously (Elmore, Lee, West, & Green, 2015). Cell quantities were determined using the spots module in Imaris.

**RNAscope in situ hybridization of SARS-CoV-2 spike RNA.** RNA in situ hybridization was performed via RNAscope 2.5 HD Red assay kit (Advanced Cell Diagnostics, Cat: 322350) in accordance with manufacturer’s instructions. Fixed tissue sections were treated with the manufacturer’s Fresh Frozen Tissue Sample Preparation Protocol, fixed in chilled 4% PFA, dehydrated, and treated with H2O2, and Protease IV before probe hybridization. Paraffinized sections were deparaffinized and treated with H2O2 and Protease Plus prior to hybridization. Probes targeting SARS-CoV-2 spike (Cat: 848561), positive-control (R-313930), and negative control DapB (Cat: 510043) were hybridized followed by proprietary assay signal amplification and detection. Tissues were counterstained with Gill’s hematoxylin. An uninfected mouse was used as a negative control and stained in parallel. Tissues were visualized using an Olympus BX60 microscope and imaged with a Nikon (Model number) camera.

**Immunocytochemical staining for SARS-CoV-2.** iPSC-derived neurons on glass-bottomed 4-well chamberslides were gently washed with 1X PBS and fixed for 1 h with 4% paraformaldehyde for removal from BSL-3 facility. Wells were subsequently washed 3 times with 1X PBS, permeabilized for 15 min at RT in 0.1% Triton-X in PBS and blocked for 2 h in a 2% BSA-5% NDS blocking solution. Cells were incubated overnight at 4°C in blocking solution with primary antibodies anti-MAP2 (EnCor Biotech Cat: NC0388389) and anti-SARS-CoV-2 nucleocapsid (Sino Bio. Cat: 40143-R019). Cells were then washed with 1X PBS and incubated in blocking solution for 2 h at RT with secondary antibodies, Alexa Fluor 594-conjugated goat anti-chicken and Alexa Fluor 488-conjugated goat anti-rabbit. After staining, cells were imaged for presence of SARS-CoV-2 nucleocapsid staining and quantified using the Revolve D75.

**ACKNOWLEDGMENTS**

This work was supported by a COVID CRAFT grant from UC Irvine Office of Research, NIH-NINDS R35 NS116835, NIH-NINDS NS041249, National Multiple Sclerosis Society grant CA-1607-25040, and support from the Ray and Tye Noorda Foundation to T.E.L. L.M.T. was supported by NIH-NINDS R35 NS116872 and K.N.G. was supported by NIH-NINDS R01NS083801. G.M.O. was supported by Immunology Research Training Grant 5T32AI060573-15, and C.S.-G. was supported by the Hereditary Disease Foundation. We
acknowledge the support of the Chafo Family Comprehensive Cancer Center Experimental Tissue Shared Resource supported by the National Cancer Institute of the National Institutes of Health under award number P30CA062203.

REFERENCES

1. Channappanavar R, Perlman S. 2020. Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity. J Clin Invest 130:6204–6213. https://doi.org/10.1172/JCI144115.

2. Song E, et al. 2021. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med 218. https://doi.org/10.1084/jem.20202135.

3. Lou JJ, et al. 2021. Neuropathology of COVID-19 (neuro-COVID): clinicopathological update. Free Neuroiat 2.

4. Virhammar J, Kumlien E, Fällmar D, Frithiof R, Jackmann S, Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, Fox JM, Chen RE, Earnest JT, Keeler SP, Ritter JH, Kang L-I, Dort S, Robichaud A, Head R, Holtzman MJ, Diamond MS. 2020. Publisher correction: SARS-CoV-2 infection of the CNS. Journal of Virology 2020;1–2. https://doi.org/10.1128/JVI.02012-06.

5. Zheng J, Wong L-Y, Li K, Yang M, Han J, Xu W, Tan W, Peng X, Jin Q, Wu G, Qin C. 2020. The pathobiology of severe acute respiratory syndrome coronavirus. J Virol 81:951–961. https://doi.org/10.1128/JVI.03089-12.

6. Held KS, Chen BP, Kuziel WA, Rollins BJ, Lane TE. 2004. Differential roles of CCL2 and CCR2 in host defense to coronavirus infection. Virology 329: 251–260. https://doi.org/10.1016/j.virology.2004.09.006.

7. Chen BP, Kuziel WA, Lane TE. 2001. Lack of CCR2 results in increased mortality and impaired leukocyte activation and trafficking following infection of the central nervous system with a neurotropic coronavirus. J Immunol 167:4585–4592. https://doi.org/10.4049/jimmunol.167.8.4585.

8. Glass WG, Hickey MJ, Hardison JL, Liu M, Manning JE, Lane TE. 2004. Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis. J Immunol 172: 4018–4025. https://doi.org/10.4049/jimmunol.172.7.4018.

9. Liu MT, Chen BP, Oertel P, Buchmeier MJ, Armstrong D, Hamilton TA, Lane TE. 2000. Cutting edge: the T cell chemoattractant IFN-inducible protein 10 is essential in host defense against viral-induced neurologic disease. J Immunol 165:2327–2330. https://doi.org/10.4049/jimmunol.165.5.2327.

10. Stiles LN, Hardison JL, Schumaur CS, Whitman LM, Lane TE. 2006. T cell anti-inflammatory effector function is not dependent on CXCL10 following murine coronavirus infection. J Immunol 177:8372–8380. https://doi.org/10.4049/jimmunol.177.12.8372.

11. Stiles LN, Liu MT, Lane JC, Lane TE. 2009. CXCL10 and trafficking of virus-specific T cells during coronavirus demyelination. Autoimmunity 42: 484–491. In Press. https://doi.org/10.1080/01420830902810708.

12. Hosking MP, Liu L, Banshoof RM, Lane TE. 2009. A protective role for ELR+ chemokines during acute viral encephalomyelitis. PLoS Pathog 5: e1000648. https://doi.org/10.1371/journal.ppat.1000648.

13. Lowery SA, Sariol A, Perlman S. 2021. Innate immune and inflammatory responses to SARS-CoV-2: implications for COVID-19. Cell Host Microbe 27:951–961. https://doi.org/10.1016/j.chom.2021.05.004.

14. Channappanavar R, Perlman S. 2017. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 39:529–539. https://doi.org/10.1007/s00281-017-0629-x.

15. Aloua S, Mubarak A, Hamed ME, Almutairi AZ, Albashri AL-A, Aljunayyin A, Enani M, Alenezi FQ, Alturkiwai W. 2021. Complement anaphylatoxins and inflammatory cytokines as prognostic markers for COVID-19 severity and in-hospital mortality. Front Immunol 12:668725. https://doi.org/10.3389/fimmu.2021.668725.

16. Huang C, Wang Y, Li X, Ren Z, Zhao J, Hu Y, Zhang L, Fang G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Miu L, Xiao Y, Gao H, Guo L, Xie J, Wang J, Jiang R, Gao Z, Jin Q, Wang J, Gao B. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.

17. Laursdans K, Jihane H, Antalosky B, Ghani D, Phan U, Hernandez R, Okeke T, Wu J, Rader D, Susztak K. 2021. Unbiased analysis of temporal changes in immune serum markers in acute COVID-19 infection with emphasis on organ failure, anti-viral treatment, and demographic characteristics. Front Immunol 12:650465. https://doi.org/10.3389/fimmu.2021.650465.

18. Levi S, Gottesman T, Sahaf Levin G, Lederfein D, Berkov E, Diker D, Levin LA, Crapser J, Zhang J, Burton EA, Trujillo JA, Fleming EL, Perlman S. 2013. Transgenic CCL2 expression in the central nervous system results in a dysregulated immune response and enhanced lethality after coronavirus infection. J Virol 87:2376–2389. https://doi.org/10.1128/JVI.03089-12.

19. Kim TS, Perlman S. 2005. Viral expression of CCL2 is sufficient to induce demyelination in RAG1–/– mice infected with a neurotropic coronavirus. J Virol 79:7113–7120. https://doi.org/10.1128/JVI.79.11.7113–7120.2005.

20. Channappanavar R, Perlman S. 2020. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model. Nat Commun 10:3758. https://doi.org/10.1038/s41467-019-11674-z.

21. Channappanavar R, Perlman S. 2013. Transgenic CCL2 expression in the central nervous system results in a dysregulated immune response and enhanced lethality after coronavirus infection. J Virol 87:2376–2389. https://doi.org/10.1128/JVI.03089-12.
patients with severe COVID-19. PLoS One 16:e0245296. https://doi.org/10.1371/journal.pone.0245296

32. Kumari P, Rothan HA, Natarek JP, Stone S, Pathak H, Strate PG, Arora K, Brinton MA, Kumar M. 2021. Neuroinvasion and encephalitis following intranasal inoculation of SARS-CoV-2 in K18-hACE2 mice. Viruses 13:132. https://doi.org/10.3390/v13010132.

33. Carossino M, et al. 2021. Fatal neuroinvasion of SARS-CoV-2 in K18-hACE2 mice is partially dependent on hACE2 expression. bioRxiv.

34. Schmitt E, Naveau M, Mechemu Y. 2010. Eukaryotic and archaeal translation initiation factor 2: a heterotrimeric tRNA carrier. FEBS Lett 584:405–412. https://doi.org/10.1016/j.febslet.2009.11.002.

35. Showkat M, Beig MA, Andrabi KL. 2014. miR-92a signaling in protein translation regulation: implications in cancer genesis and therapeutic interventions. Mol Biol Int 2014:86984. https://doi.org/10.1155/2014/86984.

36. Lane TE. 2003. Neurological manifestations of COVID-19: a comprehensive literature review and discussion of mechanisms. J Neuroimmunol 358:577658. https://doi.org/10.1016/j.jneuroim.2021.577658.

37. Matschke J, Luthergethman H, Mangel C, Sperhake JP, Schröder AS, Edler C, Mushumba H, Fitzek A, Allweiss L, Damdi M, Dottermusch M, Heinemann A, Pfefferle S, Schwablanden M, Sumner Magruder D, Bonn S, Prinz M, Gerloff C, Püschel K, Kräsmann S, Aepfelbacher M, Glatzel M. 2020. Neuropathology of patients with COVID-19 in a post-mortem case series. Lancet Neurol 19:919–929. https://doi.org/10.1016/S1474-4422(20)30308-2.

38. Song E, Bartley CM, Chow RD, Ngo TT, Jiang R, Zamecnik CR, Dandekar R, Loudemilk RP, Dai Y, Liu F, Sunshine S, Liu J, Wu W, Haves IA, Alvarenga BD, Huytn M, Tychalee A, Rahaln M, Gneg S, Geng B, Chirella A, Goldman-Isakov B, Vogels CB, Grubaud NA, Casanovas-Massana A, Phinney BS, Saleni M, Alexander JR, Gallego JA, Lenz T, Walsh H, Wapnianski AE, Mohanty S, Lucas C, Klein J, Mao T, Oh J, Ring A, Spudich S, Ko Al, Kleinstein SH, Pak J, DeRui TL. 2019. Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. Cell Rep Med 2:100288. https://doi.org/10.1016/j.crepm.2021.100288.

39. Yang AK, Kern F, Losada PH, Agar MA, Raat CA, Schartz GP, Fehlmann T, Stein JA, Schauf N, Lee DP, Calcuttawa K, Vest RT, Berdink D, Lu N, Hahn O, Gate D, McInerney MW, Channappa D, Cobos J, Ludwig N, Schulz-Schaeffer WJ, Keller A, Wyss-Coray T. 2021. Dysregulation of brain and cholesterin cell types in severe COVID-19. Nature 595:565–571. https://doi.org/10.1038/s41586-021-03710-0.

40. Karuppan MMK, Devadoss D, Nair M, Chand HS, Lakshmana MK. 2021. SARS-CoV-2 infection in the central and peripheral nervous system-associated morbidities and their potential mechanism. Mol Neurobiol 58:2465–2480. https://doi.org/10.1007/s12035-020-02245-1.

41. Akhter N, Ahmed S, Alzahrani FA, Dar SA, Wahid M, Hagne S, Bhatia K, Sr Almalki S, Alharbi RA, Sindl AAA. 2020. Impact of COVID-19 on the cerebrovascular system and the prevention of RBC lysis. Eur Rev Med Pharmacol Sci 24:10267–10278.

42. Chaia KK, Polakshare S, Bruno SD. 2020. Possible affective cognitive cerebrospinal fluid in a young patient with COVID-19 CNS vasculopathy and stroke. BMJ Case Rep 13:e237926. https://doi.org/10.1136/bcr-2020-237926.

43. MacLean MA, Kamintsky L, Leck ED, Friedman A. 2020. The potential role of microvascular pathology in the neurological manifestations of coronavirus infection. Fluids Barriers CNS 17:55. https://doi.org/10.1186/s40478-020-00126-1.

44. Thakur KT, Miller EH, Glendinning MD, Al-Dalahmah O, Banu MA, Boehme AK, Boubour AL, Bruce SS, Chong AM, Claassens J, Faust PL, Hargus G, Hickman RA, Jambawalikar S, Kandha AG, Kim CY, Klein RS, Lignell-Dipple A, Lin CC-Y, Liu Y, Miller ML, Moonis G, Nordvig AV, Overderv J, Prust ML, Przedborski S, Roth WH, Soung A, Tanji K, Teich AF, Aguillu D, Ullme-C, Goldman JE, Canoll P. 2021. COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. Brain 144:2696–2708. https://doi.org/10.1093/brain/awab148.

45. Al-Dalahmah O, Thakur KT, Nordvig AS, Prust ML, Roth W, Lignelli A, Ullme-C, Miller EH, Kunnath-Velayudhan S, Del Portillo A, Liu Y, Hargus G, Teich AF, Hickman RA, Tanji K, Goldman JE, Faust PL, Canoll P. 2020. Neuronophagia and microglial nodules in a SARS-CoV-2 patient with cerebellar hemorrhage. Acta Neuropathol Commun 8:147. https://doi.org/10.1186/s40478-020-01024-2.

46. Schwablanden M, Saliié H, Tanevski J, Killmer S, Lago MS, Shacla AE, Mayer L, Matschke J, Püschel K, Fitzek A, Onodrusscha B, Mei HE, Boettler T, Neumann-Haefelin C, Hofmann M, Breithaupt A, Genc N, Stadelmann C, Saez-Rodriquez J, Bronsert P, Knoebel K-P, Blank T, Thimme R, Glatzel M, Prinz M, Bengsch B. 2021. Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. Immunity 54:1594–1610. https://doi.org/10.1016/j.immuni.2021.06.002.

47. Consortium, H.D.J. 2012. Induced pluripotent stem cells from patients with Huntington’s disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11:264–278. https://doi.org/10.1016/j.stem.2012.04.027.

48. Smith-Geater C, Hernandez SJ, Lim RG, Adam M, Wu J, Stockdale JT, Kemp PJ, Allen ND, Fraenkel E, Thompson LM. 2020. Aberrant development of human Huntington’s disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11:264–278. https://doi.org/10.1016/j.stem.2012.04.027.